SARASOTA — Sarasota-based skin health company Omeza recently added 35 years of experience to its leadership team.
With experience in medical sales leadership, Santino Costanzo will now lead the company as the new VP and chief commercial officer, according to a statement. Using his background to his advantage, Costanzo will be in charge of developing, directing and scaling the company’s sales and marketing teams to meet strategic commercial objectives.
“Omeza is aiming to achieve market leadership by providing safe and effective omega-3 rich wound healing products, priced reasonably and so simple to deliver that doctors and nurses can apply at any site of care,” says Tom Gardner, founder and CEO, in the press release. “Having a chief commercial officer with Santino's extensive experience to guide our launch, and lead our commercialization team long-term, leaves me feeling confident that the kind of outcomes patients and payers are seeking is finally close at hand.”
In September, the company received 510(k) approval of its lead drug-device combination product, Omeza Collagen Matrix, and FDA clearance to go to market.
“I came to Omeza to develop it into a top-tier company that keeps focused on the patients, clinicians, and various sites of care,” says Costanzo. “Having seen the advantages and efficacy of its products, and met the people behind them, I see an opportunity to develop a highly skilled field force. There are many patients in the primary care setting that Omeza can and will help.”
Since 2015, Costanzo has served as director of national accounts at Organogenesis Inc. Costanzo’s previous experience also includes being VP of sales for both start-up Amniox Medical and wound care start-up Harbor MedTech. He also served as area VP of sales to wound care start-up Spiracur.